Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy

被引:25
作者
Culine, S
Theodore, C
TerrierLacombe, MJ
Droz, JP
机构
[1] INST GUSTAVE ROUSSY,DEPT MED,VILLEJUIF,FRANCE
[2] INST GUSTAVE ROUSSY,DEPT PATHOL,VILLEJUIF,FRANCE
关键词
testicular neoplasms; tumor markers; biological; drug therapy; germinoma;
D O I
10.1016/S0022-5347(01)66248-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We assessed the efficacy of primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and elevated serum tumor markers as the only evidence of disease after orchiectomy. Materials and Methods: We analyzed the outcome of 20 patients with biological disease only who received cisplatin-based (16) or carboplatin-based (4) chemotherapy as primary treatment following orchiectomy. Results: Serum tumor markers returned to normal levels in all 20 patients. One patient; required subsequent surgery for recurrent retroperitoneal mature teratoma. Two patients experienced a relapse with active disease, 1 of whom died of progressive germ cell tumor. Of the patients 19 remained free of disease 18 to 116 months after the end of treatment. Conclusions: Since results with primary retroperitoneal lymph node dissection suggest that elevated serum tumor markers usually reflect systemic metastases rather than retroperitoneal disease, primary chemotherapy seems to be the most appropriate strategy to consider in patients with biological disease only following orchiectomy.
引用
收藏
页码:1296 / 1298
页数:3
相关论文
共 20 条
[1]   RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY [J].
BAJORIN, DF ;
SAROSDY, MF ;
PFISTER, DG ;
MAZUMDAR, M ;
MOTZER, RJ ;
SCHER, HI ;
GELLER, NL ;
FAIR, WR ;
HERR, H ;
SOGANI, P ;
SHEINFELD, J ;
RUSSO, P ;
VLAMIS, V ;
CAREY, R ;
VOGELZANG, NJ ;
CRAWFORD, ED ;
BOSL, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :598-606
[2]  
BOSL GJ, 1991, CANCER, V67, P1299, DOI 10.1002/1097-0142(19910301)67:5<1299::AID-CNCR2820670505>3.0.CO
[3]  
2-4
[4]   A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS [J].
BOSL, GJ ;
GELLER, NL ;
BAJORIN, D ;
LEITNER, SP ;
YAGODA, A ;
GOLBEY, RB ;
SCHER, H ;
VOGELZANG, NJ ;
AUMAN, J ;
CAREY, R ;
FAIR, WR ;
HERR, H ;
MORSE, M ;
SOGANI, P ;
WHITMORE, W .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1231-1238
[5]  
CULINE S, 1991, EUR J CANCER, V127, P1715
[6]   THE MANAGEMENT OF PATIENTS WITH NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS WITH SEROLOGIC DISEASE ONLY AFTER ORCHIECTOMY [J].
DAVIS, BE ;
HERR, HW ;
FAIR, WR ;
BOSL, GJ .
JOURNAL OF UROLOGY, 1994, 152 (01) :111-113
[7]  
DROZ JP, 1988, CANCER, V62, P564, DOI 10.1002/1097-0142(19880801)62:3<564::AID-CNCR2820620321>3.0.CO
[8]  
2-A
[9]   LONG-TERM SURVIVORS AFTER SALVAGE HIGH-DOSE CHEMOTHERAPY WITH BONE-MARROW RESCUE IN REFRACTORY GERM-CELL CANCER [J].
DROZ, JP ;
PICO, JL ;
GHOSN, M ;
GOUYETTE, A ;
BAUME, D ;
PIOT, G ;
OSTRONOFF, M ;
THEODORE, C ;
BEAUJEAN, F ;
HAYAT, M .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (07) :831-835
[10]  
Einhorn L.H., 1992, P AN M AM SOC CLIN, V11, P196